Publications by authors named "N Aspromonte"
Diagnostic and therapeutic advances in the cardiovascular field have caused a progressive reduction in mortality from acute causes, with an ever-increasing chronicity of cardiovascular pathologies. In recent years, mechanical supports have played a fundamental role, allowing the patient to be stabilized in the most critical phase of acute heart failure (AHF) and acting as a "bridge" for definitive therapies. Heart transplantation (HTx) is the gold-standard treatment for end-stage HF, but it is burdened by a series of critical issues that limit its use, first of all the shortage of grafts.
View Article and Find Full Text PDFBackground: In acute heart failure (AHF) patients, non-invasive estimation of left ventricular filling pressures (LVFPs) appears crucial to guide management. Although poorly investigated, left atrial (LA) mechanics play a pivotal role in this setting. This report sought to assess the correlation of echocardiographic LA stiffness index with invasive LVFPs and its diagnostic accuracy as compared to other parameters used in clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- Coronary microvascular dysfunction (CMD) is important in heart failure (HF) development and progression, but its mechanisms remain complex and unclear.
- Key factors contributing to CMD include chronic inflammation, oxidative stress, and neurohormonal activation.
- Currently, there are no specific treatments for CMD, and diagnosing it can be challenging; this review will explore the connections between CMD and HF, their implications, and potential treatment opportunities.
Article Synopsis
- Iron deficiency (ID) is prevalent in heart failure (HF) patients and negatively impacts their health, even if they aren't anemic; iron supplementation can improve exercise and quality of life in these individuals.
- An online survey of 256 cardiologists revealed that most defined ID correctly and screened more than half of their patients, but only 54.3% did periodic screenings; intravenous iron was the most commonly prescribed treatment.
- The survey results point to a need for better, standardized practices for ID screening and management in HF patients, as many physicians view ID as an overlooked issue in this group.
Aims: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes.
Methods: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction.